Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ahj.2014.07.016 http://scihub22266oqcxt.onion/10.1016/j.ahj.2014.07.016 C4254508!4254508!25458644     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 298.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 298.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 298.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Am+Heart+J 2014 ; 168 (6): 823-829.e6 Nephropedia Template TP {{tp|p=25458644|t=2014. Pioglitazone for Secondary Prevention after Ischemic Stroke and Transient Ischemic Attack: Rationale and Design of the Insulin Resistance Intervention after Stroke (IRIS) Trial |pdf=|usr=}}{{25458644}} gab.com Text Pioglitazone for Secondary Prevention after Ischemic Stroke and Transient Ischemic Attack: Rationale and Design of the Insulin Resistance Intervention after Stroke (IRIS) Trial JO: Am Heart J http://www.kidney.de/pget.php?&tw=1&pmid=25458644 #FOAvip Background:: Recurrent vascular events remain a major source of morbidity and mortality after stroke or transient ischemic attack (TIA). The Insulin Resistance Intervention after Stroke (IRIS) trial is evaluating an approach to secondary prevention based on the established association between insulin resistance and increased risk for ischemic vascular events. Specifically, IRIS will test the effectiveness of pioglitazone, an insulin-sensitizing drug of the thiazolidinedione class, for reducing the risk for stroke and myocardial infarction (MI) among insulin resistant, non-diabetic patients with a recent ischemic stroke or TIA. Design:: Eligible patients for IRIS must have had insulin resistance defined by a Homeostasis Model Assessment-Insulin Resistance greater than 3.0 without meeting criteria for diabetes. Within 6 months of the index stroke or TIA, patients were randomly assigned to pioglitazone (titrated from 15mg to 45mg/day) or matching placebo and followed for up to 5 years. The primary outcome is time to stroke or MI. Secondary outcomes include time to stroke alone, acute coronary syndrome, diabetes, cognitive decline and all-cause mortality. Enrollment of 3876 participants from 179 sites in seven countries was completed in January, 2013. Participant follow-up will continue until July, 2015. Summary:: The IRIS Trial will determine whether treatment with pioglitazone improves cardiovascular outcomes of non-diabetic, insulin-resistant patients with stroke or TIA. Results are expected in early 2016. Twit Text FOAVip Pioglitazone for Secondary Prevention after Ischemic Stroke and Transient Ischemic Attack: Rationale and Design of the Insulin Resistance Intervention after Stroke (IRIS) Trial ????Am Heart J http://www.kidney.de/pget.php?&tw=1&pmid=25458644 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25458644 #FOAvip English Wikipedia <ref>{{Cite pmid|25458644}}</ref> Pioglitazone for Secondary Prevention after Ischemic Stroke and Transient Ischemic Attack: Rationale and Design of the Insulin Resistance Intervention after Stroke (IRIS) Trial #MMPMID25458644 Viscoli CM; Brass LM; Carolei A; Conwit R; Ford GA; Furie KL; Gorman M; Guarino PD; Inzucchi SE; Lovejoy AM; Parsons MW; Peduzzi PN; Ringleb P; Schwartz GG; Spence JD; Tanne D; Young LH; Kernan WN Am Heart J 2014[Dec]; 168 (6): 823-829.e6 PMID25458644show ga Background:: Recurrent vascular events remain a major source of morbidity and mortality after stroke or transient ischemic attack (TIA). The Insulin Resistance Intervention after Stroke (IRIS) trial is evaluating an approach to secondary prevention based on the established association between insulin resistance and increased risk for ischemic vascular events. Specifically, IRIS will test the effectiveness of pioglitazone, an insulin-sensitizing drug of the thiazolidinedione class, for reducing the risk for stroke and myocardial infarction (MI) among insulin resistant, non-diabetic patients with a recent ischemic stroke or TIA. Design:: Eligible patients for IRIS must have had insulin resistance defined by a Homeostasis Model Assessment-Insulin Resistance greater than 3.0 without meeting criteria for diabetes. Within 6 months of the index stroke or TIA, patients were randomly assigned to pioglitazone (titrated from 15mg to 45mg/day) or matching placebo and followed for up to 5 years. The primary outcome is time to stroke or MI. Secondary outcomes include time to stroke alone, acute coronary syndrome, diabetes, cognitive decline and all-cause mortality. Enrollment of 3876 participants from 179 sites in seven countries was completed in January, 2013. Participant follow-up will continue until July, 2015. Summary:: The IRIS Trial will determine whether treatment with pioglitazone improves cardiovascular outcomes of non-diabetic, insulin-resistant patients with stroke or TIA. Results are expected in early 2016. äPioglitazone for Secondary Prevention after Ischemic Stroke and Transi(epmc).pdf DeepDyve Pubget Overpricing